CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study

The CTMX-2051-101 study remains active and patients continue to be dosed with CX-2051 across all expansion doses - SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today provided an update on the CX-2051 Phase 1 study to address certain recent social media posts. "Since our initial data disclosure in May 2025, Phase 1 enrollment has been rapid and is substantially complete. We are on ...